DiaGenic ASA (NEL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:DiaGenic ASA (NEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014013
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DiaGenic ASA (DiaGenic) is a medical device company that develops innovative in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from the absence of dementia. DiaGenic also has IP position, unique access to biobanks and mature technology in late stage development of products for commercialization in major markets. The company’s tests are based on the observation that a focal lesion or disorder gives rise to a systemic response which can be measured in the blood. DiaGenic is headquartered in Oslo, Norway.

DiaGenic ASA (NEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
DiaGenic ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
DiaGenic ASA, Medical Devices Deals, 2011 to YTD 2017 8
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
DiaGenic ASA, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
DiaGenic Announces Rights Offering Of Shares For US$8 Million 10
DiaGenic Completes Rights Offering Of Shares For US$0.5 Million 11
DiaGenic Completes Private Placement Of Shares For US$5.2 Million 12
Asset Transactions 13
DiaGenic Plans To Sell Its Assets 13
DiaGenic ASA – Key Competitors 14
DiaGenic ASA – Key Employees 15
DiaGenic ASA – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
DiaGenic ASA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
DiaGenic ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
DiaGenic ASA, Medical Devices Deals, 2011 to YTD 2017 8
DiaGenic ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
DiaGenic Announces Rights Offering Of Shares For US$8 Million 10
DiaGenic Completes Rights Offering Of Shares For US$0.5 Million 11
DiaGenic Completes Private Placement Of Shares For US$5.2 Million 12
DiaGenic Plans To Sell Its Assets 13
DiaGenic ASA, Key Competitors 14
DiaGenic ASA, Key Employees 15

★海外企業調査レポート[DiaGenic ASA (NEL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • B3 S.A.:企業の戦略・SWOT・財務分析
    B3 S.A. - Strategy, SWOT and Corporate Finance Report Summary B3 S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a clinical stage biotechnology company that develops first-in-class precision targeted cancer drugs for the treatment of solid tumors. The company harnesses the Photoimmunotherapy (PIT) platform to develop its products. Its lead pipeline p …
  • Evotec AG (EVT)-医療機器分野:企業M&A・提携分析
    Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory dise …
  • Vicat SA:企業の戦略・SWOT・財務情報
    Vicat SA - Strategy, SWOT and Corporate Finance Report Summary Vicat SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Fomento de Construcciones y Contratas S.A.:企業の戦略・SWOT・財務分析
    Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report Summary Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone produ …
  • Insperity Inc (NSP):企業の財務・戦略的SWOT分析
    Insperity Inc (NSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Rath AG:企業の戦略・SWOT・財務情報
    Rath AG - Strategy, SWOT and Corporate Finance Report Summary Rath AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • ONEOK Partners LP (OKS)-石油・ガス分野:企業M&A・提携分析
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …
  • WABCO Holdings Inc.:企業の戦略・SWOT・財務分析
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Royal Orchid Hotels Ltd
    Royal Orchid Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Royal Orchid Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a bio-pharmaceutical company that develops, manufactures and markets genetic engineering drugs. The company offers bio-pharmaceutical products in the field of genetic engineering, p …
  • China CAMC Engineering Co Ltd (002051):企業の財務・戦略的SWOT分析
    Summary China CAMC Engineering Co Ltd (CAMC), a subsidiary of China National Machinery Industry Corp, is a construction company that offers engineering, procurement and construction services. The company designs and constructs shipyard, turnkey project in pulp plant, agricultural equipment industria …
  • Euronav NV (EURN):企業の財務・戦略的SWOT分析
    Summary Euronav NV (Euronav) is a transportation and logistics company that offers shipping services. The company provides seaborne transportation, tanker shipping, proactive management, fleet composition and ship management services. It offers ship management services which includes technical servi …
  • Nuclear Decommissioning Authority:企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Norgine B.V.:企業のM&A・事業提携・投資動向
    Norgine B.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Norgine B.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Milo Biotechnology LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Milo Biotechnology LLC (Milo) is a biotechnology company that develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The company’s pipeline product includes AAV1 (based on adeno-associated virus), which is a gene therapy for the one time treatment o …
  • Encompass Home Health and Hospice-製薬・医療分野:企業M&A・提携分析
    Summary Encompass Home Health and Hospice (Encompass), formerly CareSouth Health System Inc, is a healthcare service provider that offers nursing care services. The center provides services including home healthcare, private duty home care, hospice, and health and wellness services. It offers manage …
  • Ganymed Pharmaceuticals AG-製薬・医療分野:企業M&A・提携分析
    Summary Ganymed Pharmaceuticals AG (Ganymed) is a biopharmaceutical company that manufactures and distributes monoclonal antibodies for the treatment of solid cancers. The company conducts clinical trials to manufacture various drug candidates. It also offers antibody cancer drugs and IMABS for mono …
  • Nationwide Building Society:企業の戦略・SWOT・財務分析
    Nationwide Building Society - Strategy, SWOT and Corporate Finance Report Summary Nationwide Building Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆